Inovio Pharmaceuticals, Inc. (INO) shareholders
Close on Nov 17, 2026Market cap $168.54MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (14.50%) | 15,364,105 | 14.50% | 13G (passive) amendment | Sep 30, 2026 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 10,666,523 | 9.90% | 13G (passive) | Jul 31, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (13.50%) | 9,339,614 | 13.50% | 13G (passive) amendment | Mar 31, 2026 |
| Janus Henderson Group PLC | 6,666,295 | 9.99% | 13G (passive) amendment | Nov 28, 2025 |
| Highbridge Capital Management LLC | 6,190,475 | 8.20% | 13G (passive) amendment | Mar 31, 2026 |
| Adage Capital Management, L.P. Joint filing with Robert Atchinson (5.84%), Phillip Gross (5.84%) | 4,233,529 | 5.84% | 13G (passive) amendment | Mar 31, 2026 |
| Vanguard Capital Management | 4,161,566 | 5.05% | 13G (passive) | Jun 30, 2026 |
| Alyeska Fund GP, LLC Joint filing with Alyeska Investment Group, L.P. (5.99%), Anand Parekh (5.99%) | 4,000,000 | 5.99% | 13G (passive) amendment | Dec 31, 2025 |
| Highbridge Capital Management, LLC | 3,633,333 | 9.20% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of INO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 8,454,797 | 8.18% | $9.30M | −884,817 | 0.00% |
| Jupiter Topco LLC | 5,171,053 | 5.00% | $5.71M | New | 0.00% |
| Vanguard Capital Management LLC | 3,650,562 | 3.53% | $4.02M | +749,354 | 0.00% |
| Boxer Capital Management, LLC | 2,844,994 | 2.75% | $3.13M | +474,872 | 0.24% |
| ADAR1 Capital Management, LLC | 2,143,910 | 2.07% | $2.36M | +673,802 | 0.11% |
| D. E. Shaw & Co., Inc. | 1,351,656 | 1.31% | $1.49M | −861,163 | 0.00% |
| Two Sigma Investments, LP | 1,239,778 | 1.20% | $1.36M | +849,394 | 0.00% |
| Eversept Partners, LP | 1,035,360 | 1.00% | $1.14M | – | 0.06% |
| Geode Capital Management, LLC | 802,751 | 0.78% | $883.75K | +1,247 | 0.00% |
| Millennium Management LLC | 796,107 | 0.77% | $875.72K | −614,738 | 0.00% |
| BlackRock, Inc. | 779,057 | 0.75% | $856.96K | +116,876 | 0.00% |
| Vanguard Fiduciary Trust Co | 480,769 | 0.46% | $528.85K | +88,703 | 0.00% |
| Caption Management, LLC | 478,950 | 0.46% | $526.85K | New | 0.00% |
| Renaissance Technologies LLC | 361,339 | 0.35% | $397.47K | −282,438 | 0.00% |
| State Street Corp | 336,610 | 0.33% | $370.27K | +40,300 | 0.00% |
| Gsa Capital Partners Llp | 265,011 | 0.26% | $292.00K | −64 | 0.02% |
| UBS Group AG | 262,320 | 0.25% | $288.55K | +12,670 | 0.00% |
| Quadrature Capital Ltd | 258,928 | 0.25% | $284.82K | New | 0.00% |
| Citadel Advisors LLC | 241,775 | 0.23% | $265.95K | −44,577 | 0.00% |
| Northern Trust Corp | 174,394 | 0.17% | $191.83K | −124,476 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 102 | 33M | 31.7% | 23 / 27 | 15 / 18 | 10M | 5M |
| Q1 2026 | 99 | 31M | 30.3% | 16 / 19 | 23 / 15 | 5M | 4M |
| Q4 2025 | 101 | 33M | 31.9% | 20 / 25 | 22 / 18 | 16M | 4M |
| Q3 2025 | 99 | 21M | 20.1% | 24 / 21 | 28 / 28 | 14M | 4M |
| Q2 2025 | 103 | 10M | 10.0% | 24 / 23 | 29 / 28 | 2M | 5M |
| Q1 2025 | 107 | 14M | 13.2% | 18 / 33 | 27 / 13 | 3M | 3M |
| Q4 2024 | 104 | 13M | 12.9% | 26 / 34 | 14 / 20 | 5M | 1M |
| Q3 2024 | 98 | 9M | 8.3% | 21 / 26 | 20 / 16 | 3M | 1M |
| Q2 2024 | 96 | 8M | 7.8% | 31 / 21 | 18 / 21 | 5M | 1M |
| Q1 2024 | 87 | 4M | 4.1% | 83 / 1 | 3 / 3 | 4M | 0M |
| Q4 2023 | 7 | 0M | 0.0% | 7 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
19 funds held INO in Q2 2026, 29% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of INO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Small Cap Growth Fund | 6,993,661 | 6.76% | $4.73M | 0.05% | Jul 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 3,535,483 | 3.42% | $2.39M | 0.05% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,600,092 | 2.51% | $2.86M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 963,325 | 0.93% | $1.06M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 348,001 | 0.34% | $455.88K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 280,138 | 0.27% | $308.15K | 0.02% | Jun 30, 2026 |
| Ultra-Small Company Fund | 173,000 | 0.17% | $190.30K | 0.19% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 104,005 | 0.10% | $136.25K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 96,119 | 0.09% | $125.92K | 0.00% | May 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 67,976 | 0.07% | $74.77K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 45,128 | 0.04% | $49.64K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 45,041 | 0.04% | $59.00K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 42,017 | 0.04% | $46.22K | 0.00% | Jun 30, 2026 |
| Tiff Multi-Asset Fund | 21,590 | 0.02% | $23.75K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 18,882 | 0.02% | $20.77K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jacqueline Elizabeth Shea | Chief Executive Officer, Director | 111,021 | 0.11% | May 21, 2026 |
| Peter Kies | CFO | 47,917 | 0.05% | May 21, 2026 |
| Laurent Humeau | Chief Scientific Officer | 48,986 | 0.05% | May 21, 2026 |
| Michael John Sumner | Chief Medical Officer | 42,038 | 0.04% | May 21, 2026 |
| Lota S. Zoth | Director | 8,726 | 0.01% | May 21, 2026 |
| Jay Shepard | Director | 9,209 | 0.01% | May 21, 2026 |
| Roger D. Dansey | Director | 8,916 | 0.01% | May 21, 2026 |
| Ann Calby Miller | Director | 9,877 | 0.01% | May 21, 2026 |
| Simon X. Benito | Director | 12,191 | 0.01% | May 21, 2026 |
| David B. Weiner | Director | 87,592 | 0.08% | May 21, 2026 |
| Wendy L. Yarno | Director | 10,512 | 0.01% | May 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael John Sumner Chief Medical Officer | May 20, 2026 | Tax withholding | −2,693 | $1.23 | $3.31K | 42,038 |
| Michael John Sumner Chief Medical Officer | May 20, 2026 | Option exercise | +9,450 | – | – | 44,731 |
| Peter Kies CFO | May 20, 2026 | Option exercise | +8,700 | – | – | 47,542 |
| Peter Kies CFO | May 20, 2026 | Tax withholding | −4,688 | $1.23 | $5.77K | 42,854 |
| Laurent Humeau Chief Scientific Officer | May 20, 2026 | Option exercise | +6,027 | – | – | 48,986 |
| Laurent Humeau Chief Scientific Officer | May 20, 2026 | Tax withholding | −2,163 | $1.23 | $2.66K | 46,823 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 20, 2026 | Tax withholding | −12,306 | $1.23 | $15.14K | 111,021 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 20, 2026 | Option exercise | +28,296 | – | – | 123,327 |
| Peter Kies CFO | May 15, 2026 | Option exercise | +4,771 | – | – | 41,413 |
| Peter Kies CFO | May 15, 2026 | Tax withholding | −2,571 | $1.30 | $3.34K | 38,842 |
| Michael John Sumner Chief Medical Officer | May 15, 2026 | Tax withholding | −680 | $1.30 | $884 | 35,281 |
| Michael John Sumner Chief Medical Officer | May 15, 2026 | Option exercise | +2,385 | – | – | 35,961 |
| Laurent Humeau Chief Scientific Officer | May 15, 2026 | Tax withholding | −1,712 | $1.30 | $2.23K | 42,959 |
| Laurent Humeau Chief Scientific Officer | May 15, 2026 | Option exercise | +4,771 | – | – | 44,671 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 15, 2026 | Option exercise | +17,744 | – | – | 102,748 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 15, 2026 | Tax withholding | −7,717 | $1.30 | $10.03K | 95,031 |
| Michael John Sumner Chief Medical Officer | Mar 31, 2026 | Option exercise | +4,292 | – | – | 34,799 |
| Michael John Sumner Chief Medical Officer | Mar 31, 2026 | Tax withholding | −1,223 | $1.74 | $2.13K | 33,576 |
| Michael John Sumner Chief Medical Officer | Feb 26, 2026 | Option exercise | +5,010 | – | – | 22,860 |
| Michael John Sumner Chief Medical Officer | Feb 26, 2026 | Option exercise | +11,550 | – | – | 34,410 |
| Michael John Sumner Chief Medical Officer | Feb 26, 2026 | Tax withholding | −3,903 | $1.79 | $6.99K | 30,507 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2026 | Option exercise | +7,366 | – | – | 42,934 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2026 | Tax withholding | −2,064 | $1.79 | $3.69K | 35,568 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2026 | Option exercise | +5,010 | – | – | 37,632 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2026 | Tax withholding | −3,034 | $1.79 | $5.43K | 39,900 |
| David B. Weiner Director | Feb 26, 2026 | Option exercise | +972 | – | – | 87,592 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | Feb 26, 2026 | Tax withholding | −8,057 | $1.79 | $14.42K | 70,260 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | Feb 26, 2026 | Option exercise | +28,401 | – | – | 98,661 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | Feb 26, 2026 | Tax withholding | −13,657 | $1.79 | $24.45K | 85,004 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | Feb 26, 2026 | Option exercise | +18,632 | – | – | 78,317 |
| Peter Kies CFO | Feb 26, 2026 | Tax withholding | −6,294 | $1.79 | $11.27K | 36,642 |
| Peter Kies CFO | Feb 26, 2026 | Option exercise | +5,010 | – | – | 35,267 |
| Peter Kies CFO | Feb 26, 2026 | Option exercise | +10,634 | – | – | 42,936 |
| Peter Kies CFO | Feb 26, 2026 | Tax withholding | −2,965 | $1.79 | $5.31K | 32,302 |
| Michael John Sumner Chief Medical Officer | Jun 30, 2025 | Option exercise | +2,916 | – | – | 17,850 |
| Simon X. Benito Director | May 21, 2025 | Option exercise | +2,167 | – | – | 12,191 |
| Ann Calby Miller Director | May 21, 2025 | Option exercise | +2,167 | – | – | 9,877 |
| Jay Shepard Director | May 21, 2025 | Option exercise | +2,167 | – | – | 9,209 |
| Wendy L. Yarno Director | May 21, 2025 | Option exercise | +2,167 | – | – | 10,512 |
| Roger D. Dansey Director | May 21, 2025 | Option exercise | +2,167 | – | – | 8,916 |
| David B. Weiner Director | May 21, 2025 | Option exercise | +2,167 | – | – | 86,620 |
| Lota S. Zoth Director | May 21, 2025 | Option exercise | +2,167 | – | – | 8,726 |
| Michael John Sumner Chief Medical Officer | May 15, 2025 | Option exercise | +2,385 | – | – | 15,614 |
| Michael John Sumner Chief Medical Officer | May 15, 2025 | Tax withholding | −680 | $1.95 | $1.33K | 14,934 |
| Peter Kies CFO | May 15, 2025 | Tax withholding | −2,566 | $1.95 | $5.00K | 30,257 |
| Peter Kies CFO | May 15, 2025 | Option exercise | +4,771 | – | – | 32,823 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 15, 2025 | Tax withholding | −7,717 | $1.95 | $15.05K | 59,685 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 15, 2025 | Option exercise | +17,744 | – | – | 67,402 |
| Laurent Humeau Chief Scientific Officer | May 15, 2025 | Tax withholding | −1,708 | $1.95 | $3.33K | 32,622 |
| Laurent Humeau Chief Scientific Officer | May 15, 2025 | Option exercise | +4,771 | – | – | 34,330 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 10, 2025 | Option exercise | +5,500 | – | – | 52,050 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 10, 2025 | Tax withholding | −2,392 | $1.80 | $4.31K | 49,658 |
| David B. Weiner Director | Feb 26, 2025 | Option exercise | +972 | – | – | 84,453 |
| David B. Weiner Director | Feb 26, 2025 | Option exercise | +972 | – | – | 83,481 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2025 | Option exercise | +5,010 | – | – | 31,618 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2025 | Tax withholding | −2,059 | $1.98 | $4.08K | 29,559 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2025 | Option exercise | +3,855 | – | – | 28,192 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2025 | Tax withholding | −1,584 | $1.98 | $3.14K | 26,608 |
| Peter Kies CFO | Feb 26, 2025 | Tax withholding | −2,960 | $1.98 | $5.86K | 28,052 |
| Peter Kies CFO | Feb 26, 2025 | Option exercise | +5,010 | – | – | 31,012 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Inovio Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 234,629 shares on Aug 26, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lota S. Zoth Director | Jun 5, 2023 | 5,700 | $3.21K | Jun 5, 2023 | Restricted Stock |
Congress trades
1 trade in Inovio Pharmaceuticals reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Christopher L. Jacobs NY27 | Sold | Sep 8, 2020 | $1K–15K | Nov 6, 2020 59 days late |
See a number that looks wrong?